LIFECORE BIOMEDICAL, INC. Impairment of Intangible Assets, Indefinite-lived (Excluding Goodwill)
LIFECORE BIOMEDICAL, INC. (LFCR) reported Impairment of Intangible Assets, Indefinite-lived (Excluding Goodwill) of $14.15 million for the 12-month period ending 2022-05-29, per its 10-K/A filed 2023-03-16.
Discontinued › Expense Statement › Operating Expenses
us-gaap:ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill · last filed 2023-03-16
- LIFECORE BIOMEDICAL, INC. impairment of intangible assets, indefinite-lived (excluding goodwill) for the quarter ending 2016-05-29 was $0.00.
- LIFECORE BIOMEDICAL, INC. impairment of intangible assets, indefinite-lived (excluding goodwill) for the quarter ending 2016-02-28 was $34.00M.
- LIFECORE BIOMEDICAL, INC. impairment of intangible assets, indefinite-lived (excluding goodwill) for fiscal 2022 was $14.15M.
- LIFECORE BIOMEDICAL, INC. impairment of intangible assets, indefinite-lived (excluding goodwill) for fiscal 2021 was $0.00.
- LIFECORE BIOMEDICAL, INC. impairment of intangible assets, indefinite-lived (excluding goodwill) for fiscal 2019 was $2.00M.
- LIFECORE BIOMEDICAL, INC. impairment of intangible assets, indefinite-lived (excluding goodwill) for fiscal 2018 was $0.00.
| Period end | Impairment of Intangible Assets, Indefinite-lived (Excluding Goodwill) | Impairment of Intangible Assets, Indefinite-lived (Excluding Goodwill) 3 month | Impairment of Intangible Assets, Indefinite-lived (Excluding Goodwill) 6 month | Impairment of Intangible Assets, Indefinite-lived (Excluding Goodwill) 9 month | Impairment of Intangible Assets, Indefinite-lived (Excluding Goodwill) 12 month |
|---|---|---|---|---|---|
| 2022-05-29 | $14.15M 10-K/A · filed 2023-03-16 | ||||
| 2021-05-30 | $0.00 10-K/A · filed 2023-03-16 | ||||
| 2019-05-26 | $2.00M 10-K · filed 2019-08-01 | ||||
| 2018-05-27 | $0.00 10-K · filed 2019-08-01 | ||||
| 2017-05-28 | $0.00 10-K · filed 2019-08-01 | ||||
| 2017-02-27 | $0.00 10-K/A · filed 2018-03-15 | ||||
| 2016-05-29 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2018-08-09 | $34.00M derived: sum of 2 quarters · filed 2018-08-09 | $34.00M 10-K · filed 2018-08-09 | ||
| 2016-02-28 | $34.00M 10-Q · filed 2017-04-07 | $34.00M 10-Q · filed 2017-04-07 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| ADC Therapeutics SA (ADCT) | $0.163B | -1.39 | |
| Minerva Neurosciences, Inc. (NERV) | United States | $0.165B | -0.66 |
| Tonix Pharmaceuticals Holding Corp. (TNXP) | United States | $0.166B | -1.34 |
| Annexon, Inc. (ANNX) | United States | $0.147B | -4.22 |
| Corbus Pharmaceuticals Holdings, Inc. (CRBP) | United States | $0.144B | -1.72 |
| Organogenesis Holdings Inc. (ORGO) | United States | $0.182B | -3.70 |
| SPRUCE BIOSCIENCES, INC. (SPRB) | United States | $0.142B | -2.89 |
| Korro Bio, Inc. (KRRO) | United States | $0.141B | -1.81 |
| AN2 Therapeutics, Inc. (ANTX) | United States | $0.185B | -4.84 |
| Atrium Therapeutics, Inc. (RNA) | United States | $0.140B |